Researchers have explored the potential of this novel therapeutic approach, demonstrating promising pre-clinical data with over 40 scientific papers. Vectored-antibody delivery using rAAV offers advantages in treatment of various chronic and infectious diseases.
A 2015 NIH study analyzed daily gene activation in an Ebola patient and found a marked decline in antiviral responses before virus clearance from white blood cells. The study showed host responses shifted toward cellular and organ repair, coinciding with clinical improvement.
Researchers analyzed a patient's progression through Ebola virus disease and recovery to identify distinct phases of physiological responses. The study also characterized serum from healthy volunteers receiving the rVSV-ZEBOV vaccine, identifying six markers that predict adverse reactions.
An international effort analyzed 1,610 Ebola virus genomes from the 2013-2016 West African epidemic, revealing insights into factors that sped or slowed the outbreak. The study found that cities played a major role in the magnitude of the epidemic and that distance between cities was key to sparing nearby regions from severe epidemics.
A recent study suggests that current CDC and WHO guidelines may not be sufficient to protect sewer workers from the risk of contracting Ebola through inhalation. The researchers found that worker inhalation exposure to Ebolavirus-contaminated aerosols in the sewer is a concern that needs to be addressed.
A large clinical trial is being conducted to identify the most promising Ebola vaccination regimens to protect people from the disease. The PREVAC trial will enroll over 5,000 adults and children in Guinea, Liberia, and Sierra Leone to evaluate three experimental vaccine strategies.
A successful antibody treatment protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected. Monoclonal antibodies show promise in providing protection during advanced stages of disease with highly dangerous viruses.
Scientists have successfully treated guinea pigs and rhesus monkeys with a monoclonal antibody to cure Marburg and Ravn viruses. The treatment, MR191-N, provided up to 100% protection when administered within 5 days of infection, offering new hope for preventing and treating filovirus outbreaks.
During the West African Ebola crisis, bushmeat consumption decreased overall, but remained constant for wealthier households. Knowledge about Ebola risks reduced consumption among households that knew the risks.
A recent study by Indiana University researchers has mapped a key protein of the Zika virus, enabling the analysis of existing drugs and compounds that can disrupt its spread. The study's findings offer hope for finding effective treatments against the disease, which causes birth defects and neurological disorders in infants and adults.
Researchers found that inhibiting Toll-like receptor 4 activation can silence Ebola virus-infected macrophages, a potential treatment option. The study also suggests this approach could work for other hemorrhagic fever viruses.
A pilot study of an interferon drug has shown promising results in treating Ebola patients, with a 67% increase in survival rates compared to those receiving only supportive care. The treatment also relieved clinical symptoms such as abdominal pain and diarrhea earlier than those not treated with the drug.
New research examines the impact of Ebola virus proteins packaged in exosomes on the immune system, impairing its ability to fight off the infection. The study highlights the potential for exosomal VP40 to have a substantial impact on Ebola virus disease.
A Phase 1 clinical trial found that a two-vaccine regimen against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers. The investigational vaccines used harmless viral vectors to deliver proteins of the Ebola virus, prompting an immune response.
A new study found that Ebola vaccines provide durable immune responses at one year after vaccination, with 100% of recipients retaining Ebola virus glycoprotein-specific antibodies. The heterologous primary and booster vaccination schedule showed long-lasting immunity, exceeding eight months after primary immunization.
A Georgia State University researcher has received a five-year grant to develop a new drug targeting the Ebola virus. The goal is to find compounds that block the growth of Ebola virus by inhibiting its viral machinery.
Scientists have identified a previously unknown virus affecting parasitoid wasp species, reducing female offspring and extending lifespan. The discovery has implications for understanding viral transmission in insects.
A new oral Ebola vaccine has shown effectiveness in a chimpanzee trial, offering hope for conserving wild ape populations threatened by diseases like Ebola and anthrax. However, the closure of captive chimpanzee facilities due to changing laws may hinder further research and development.
A study published in the Public Library of Science Pathogens found that Zika virus targets neuronal, lymph, joint, muscle and genital/urinary/reproductive tissues, persisting for at least 35 days. The research provides insights into the growth and distribution of the virus in human tissues.
The Nextstrain software tool has won the first-ever international Open Science Prize for its ability to track genetic mutations during disease outbreaks. The platform makes it easier to share and analyze genetic sequencing data, aiming to speed discoveries and improve human health.
A combination of two cancer drugs has been found to inhibit both dengue and Ebola virus infections in mice, with efficacy also shown against West Nile and Zika viruses. The study identified a molecular mechanism by which the drugs disrupt RNA viruses' genetic material.
A new study investigated the potential role of North American animals as hosts for Zika virus. Researchers tested common animal species, including goats, pigeons, raccoons, and ducks, for infectious virus presence and antibodies. The findings suggest that these animals may serve as an unseen reservoir for Zika virus in urban environments.
Researchers at the University of Kent have found that Ebolaviruses require fewer than five mutations to adapt to new host species, including rodents. This finding highlights the potential for these viruses to spread beyond their natural range and increase the risk to humans.
A new study found that Ebola superspreaders were responsible for infecting 61% of all cases in the 2014-15 outbreak. These superspreaders often fit into certain age groups and continue to spread disease after being placed in care facilities.
A Queensland-led team has developed an effective and economical Ebola treatment made with antibodies from horses, which could be used in the next outbreak. The post-exposure treatment is a cost-effective alternative to monoclonal antibodies, which require significant investment for scale-up and manufacture.
A novel mRNA vaccine has shown promise in protecting mice and monkeys against Zika virus infection. The vaccine, which uses messenger RNA to produce Zika virus proteins, was found to be highly effective in preventing the virus in both animal models.
A team of experts reviewed post-Ebola reports to identify key problems and recommendations for reform. They found significant gaps between proposed changes and actual action, particularly in strengthening compliance with International Health Regulations.
Scientists have identified a 'molecular barcode' in blood samples from Ebola patients that can predict survival or death. The analysis provides data on the underlying causes of Ebola virus infection and suggests a potential diagnostic tool to guide treatment strategies.
Researchers at UM SOM and SOD published 22 articles on infectious agents, vaccines, and immune system activation. Studies focused on Ebola, Clostridium difficile, biofilms, and other topics, advancing knowledge in infection and immunity research.
Researchers used a new mouse model to study how the Ebola virus affects the immune system, focusing on cellular signaling events. They found that macrophages play a critical role in controlling EBOV infection by producing MAVS, which helps limit organ damage and promotes type I interferon production.
A team of scientists has identified a mechanism to counteract Ebola's ability to spread, revealing that host cells sequester viral proteins away from the plasma membrane. This discovery could lead to a novel antiviral strategy against Ebola.
The study reveals differences in protein arrangement between immature Zika and other flaviviruses, shedding light on the virus's role in infection and disease. Understanding the structure of the immature form could help develop effective antiviral treatments and vaccines for diseases like microcephaly.
Scientists discovered Ebola virus RNA lingering in the lungs of a recovering patient for about five days after it cleared from blood. The findings support the possibility of active replication in the lungs, raising potential roles for lung infection in the disease's pathogenesis and transmission.
An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, showing no cases among those vaccinated within 10 days. The vaccine's efficacy also led to indirect protection through herd immunity in unvaccinated people, providing weight to early trial results.
Researchers analysed viromes in blood samples from patients with Ebola symptoms, finding potential links between co-infected pathogens and worsening clinical outcomes. The study aims to identify new pathogens and improve diagnosis for other VHFs.
Researchers developed algorithms to track Ebola epidemic spread, revealing that most infected individuals stayed within their districts. The study's findings suggest using this method could inform effective control measures for new emerging epidemics.
A modified rabies virus expressing a protein from the MERS virus protects mice against both diseases. The dual compound could lead to an effective human vaccine for Middle East Respiratory Syndrome and prevent its spread in camels.
Researchers at UTMB engineered Ebola virus variants to study the components disabling the human immune system. The study found that IIDs promote replication of viral particles in cells and counteract the activity of immune cells.
Researchers successfully developed a vaccine against influenza using genetically modified live virus that activates the immune system but cannot replicate in healthy cells. The new vaccine proved effective in mice, guinea pigs, and ferrets, offering an antibody response comparable to existing vaccines.
A study published in PLOS Neglected Tropical Diseases found that tens of individuals in Sierra Leone showed no signs of Ebola disease but still tested positive for antibodies, suggesting a minority may contract the virus without symptoms. The discovery raises questions about the scope of the 2013-2016 outbreak and potential transmissio...
A Stanford-led study identified 14 individuals in Sierra Leone who had Ebola antibodies but no symptoms, contradicting previous assumptions about the disease's severity. The research suggests that 25% of Ebola infections were minimally symptomatic, and public health efforts may not have been effective in containing the virus.
Research finds that the Zika virus can survive on hard, non-porous surfaces for up to eight hours, especially when associated with blood. However, commonly used disinfectants such as isopropyl alcohol and quaternary ammonium/alcohol are effective in killing the virus in a short period.
Researchers at the University of Sussex have discovered how the Epstein-Barr virus controls two genes involved in cancer development, MYC and BCL2L11. The study found that the virus hijacks enhancer DNA regions to turn on or off these genes, leading to blood cancer development.
A new antimalarial compound, pyronaridine, has shown promising activity against the Ebola virus in laboratory tests. The compound, already approved for use in Europe, was identified through a machine learning model and is being tested in vivo to assess its potential as an Ebola treatment.
A human antibody that neutralizes Zika virus has been shown to reduce levels of the virus in placental and fetal tissues and decrease fetal disease in a mouse model of Zika infection. The findings suggest that this antibody could be developed to protect pregnant women and others from Zika-related complications.
Researchers found mutations in Ebola virus that increased its ability to infect human cells, potentially contributing to the outbreak's spread. The mutations did not affect the virus's ability to infect other mammalian species, including fruit bats.
A new study co-led by TSRI scientists suggests that Ebola virus gained a genetic mutation, GP-A82V, which helps it better target human cells. This mutation emerged early in the epidemic and caused about 90% of infections during the recent outbreak.
Researchers found that Zika virus infection can severely damage the testes of male mice, causing shrinkage and reduced sperm count. The study suggests that this may have important implications for human males infected with the virus, highlighting the need for further research on reproductive health.
Antibodies from Ebola survivors can strongly neutralize the virus and protect mice from a lethal challenge. The study found these protective antibodies using a new technology called Immune Repertoire Capture°0niversity.
A recent study by Emory Vaccine Center-India collaboration reveals insights into CD8 T cells' role in fighting dengue virus infection. The research shows that these immune cells expand massively but keep cytokine production under control, retaining the ability to kill virus-infected cells.
Researchers found that Zika virus disrupts fetal brain development by interfering with human neural progenitor cells, leading to microcephaly. They also identified specific small RNAs from the virus that could impact brain development and lead to microcephaly in mice.
Researchers at Michigan Technological University provide a detailed overview of Zika's history, transmission modes, and risks, including sexual transmission and miscarriage risks. The study also highlights the connection between dengue virus infection and Zika virus exacerbation.
Researchers found that Zika virus infection damages placental cells and enhances entry of the virus through HSV-2 receptors. Fetuses in pregnant women with HSV-2 infection are at higher risk for microcephaly and other effects caused by Zika virus.
A team of researchers has successfully isolated Zika virus from a semen sample, obtaining the first complete genome sequence of the virus in humans. The study provides valuable insights into potential sexual transmission of Zika virus, which was previously poorly understood.
A randomized controlled trial found ZMapp to be safe and well-tolerated, with a 40% lower risk of death for those who received the treatment. However, the trial was conducted during a public health emergency and enrolled too few participants to determine definitively whether ZMapp is superior to standard care alone.
A new screening strategy could quickly identify drugs with antiviral potential by repurposing existing medications for other conditions. The research revealed 110 human genes that could serve as antiviral targets for specific existing drugs.
A new therapeutic strategy targeting a shared Achilles' heel of all Ebola viruses has shown promising results. Two monoclonal antibodies blocked the invasion of human cells by all five ebolaviruses, and one protected mice exposed to lethal doses of Ebola Zaire.
Scientists have developed a two-pronged antibody that can counteract the unique immune-evasion mechanism of filoviruses like Ebola. The antibody, called a 'Trojan horse' antibody, targets the glycoprotein on the outside of the virus and prevents it from associating with a specific host-cell receptor in the endosome.
Researchers have found Zika virus genetic material in human tears and live virus in mouse eyes, raising questions about transmission through bodily fluids. The study's findings have implications for corneal transplantation and potential new diagnostic methods, such as testing tear samples for viral RNA or antibodies.
Researchers developed a new mathematical model to predict zoonotic disease outbreaks like Ebola and Lassa fever. The model incorporates spillover and stuttering transmission, enabling more accurate predictions and informing targeted public health strategies.